PVLA

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Wall Street analysts forecast PVLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PVLA is 132.55 USD with a low forecast of 70.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Palvella Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Palvella Therapeutics Inc. EPS for the last quarter amounts to -1.03 USD, decreased -73.86 % YoY.

Palvella Therapeutics Inc (PVLA) has 14 emplpoyees as of January 07 2026.

Today PVLA has the market capitalization of 1.07B USD.